![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
血小板缺血与免疫检查点抑制剂的关联:基于FDA不良事件报告系统数据库数据的大规模药监测分析
Geliang Liu1,2,3, Shuxian Zhang1,3, Zhuang Mo1,4
1Shanxi Key Laboratory of Big Data for Clinical Decision, Shanxi Medical University, Taiyuan, China.
Frontiers in pharmacology
|July 2, 2024
概括
免疫检查点抑制剂 (ICI) 可以引起与免疫相关的不良事件 (irAEs),包括免疫血小板缩 (ITP). 联合治疗,特别是抗PD-1与抗CTLA-4的联合治疗,会增加ITP的风险,尤其是在治疗60天内的黑色素瘤患者中.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 药物监督 药物监督 药物监督
背景情况:
- 免疫检查点抑制剂 (ICI) 在癌症治疗中至关重要,但可以诱导与免疫相关的不良事件 (irAEs).
- 免疫性血栓缩 (ITP) 是与ICI相关的显著的irAE,需要更深入地了解其临床特征和潜在机制.
研究的目的:
- 使用FAERS数据库调查ICI诱导的ITP的临床特征.
- 通过整合TCGA泛癌数据,探索ICI诱导的ITP的潜在生物机制.
主要方法:
- 在FAERS (2012-2022) 中对ICI不良反应报告的不成比例性分析 (ROR,PRP,BCPNN,MGPS).
- 对TCGA转录组数据的分析,以确定潜在的生物途径,涉及ICI诱导的ITP.
主要成果:
- 发现了345份ICI诱导的ITP报告,84%与单疗法相关,16%与组合疗法相关.
- 受影响患者的平均年龄为69岁,死亡率为18%,危及生命的结果为13.6%.
- ITP的中位发病时间是剂后42天;抗PD-1加抗CTLA-4的风险更高,特别是在60天内黑色素瘤患者中.
结论:
- 与特定ICI (nivolumab, pembrolizumab等) 相关的ITP的重要报告信号 和组合药物 (尼沃卢马布/伊皮利穆马布).
- 潜在的机制包括mTORC1信号通路失调和巨核细胞功能障碍.
- 建议在ICI治疗的黑色素瘤患者密切监测ITP,特别是在治疗的前60天内.
更多相关视频
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
1.3K
06:07Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
5.7K
相关概念视频
01:27Tumor Immunotherapy
510
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
510
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
517
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
517